Search results
1 company and 10 research reports found for "Antisoma"
Company results
- Antisoma
Antisoma is a UK biotech company which specialised in the development of novel cancer therapies. Fol...
Sector reports
No sector reports have been found.
Research results
Antisoma
Not to be
Update | Pharmaceutical & Healthcare | 01/02/2011Antisoma yesterday delivered a double dose of negative news with the failure of both the ACCEDE Phase III trial of AS1413 and the Phase IIb study of A...
Antisoma
To be, or not to be...
Review | Pharmaceutical & Healthcare | 17/11/2010The Shakespearean tragedy that is Antisoma continues to play out following the failure of the ATTRACT-2 study of ASAS404 and the termination of the li...
Antisoma
Slings and arrows...
Update | Pharmaceutical & Healthcare | 30/03/2010Antisoma has reported the failure of the ATTRACT-1 study of ASA404 in first line non-small cell lung cancer. The outcome of the interim analysis of th...
Antisoma
Risk/reward improving
Review | Pharmaceutical & Healthcare | 19/02/2010Antisoma offers one of the most attractive biotech investments in the UK, but it remains heavily geared to the success of three ongoing Phase III stud...
Antisoma
Interim analyses next
Outlook | Pharmaceutical & Healthcare | 23/09/2009With a lead compound partnered with Novartis and three other cancer projects in clinical trials, Antisoma offers one of the most attractive risk-rewar...
Antisoma
Trial plans in mBC
Company Comment - Interim results | Pharmaceutical & Healthcare | 16/02/2009Antisoma’s partner Novartis is to study ASA404 in a second cancer indication of metastatic breast cancer (mBC), but the studies will be Phase II...
Antisoma
ASH data
Company Comment - Clinical trial update | Pharmaceutical & Healthcare | 10/12/2008Antisoma has reported additional data from studies of two key pipeline products, AS1411 and AS1413, at the American Society of Hematology (ASH), a key...
Antisoma
Novartis actions key
Company Comment - Full year results | Pharmaceutical & Healthcare | 19/09/2008Antisoma’s investment case pivots upon decisions to be taken over the next year by Novartis, in relation to ASA404. In particular, when or wheth...
Antisoma
Novartis funding mitigates risk
Company Comment - Funding | Pharmaceutical & Healthcare | 25/02/2008Antisoma is one of only a few companies in the UK biotech sector without a near-term funding requirement, boasting a significant cash balance thanks t...
Antisoma
Company Comment
Company Comment | Pharmaceutical & Healthcare | 13/10/2005Antisoma is a biopharmaceutical company that is developing products for the treatment of cancer. ...
